Overview

STATEMENT OF NEED

Myeloproliferative neoplasms are a heterogeneous group of hematopoietic disorders that includes myelofibrosis, polycythemia vera (PV), and essential thrombocythemia (ET). These malignancies affect approximately 13,000, 134,000, and 148,000 individuals in the United States, respectively. As symptoms do not typically manifest in early stages, patients with MPNs often present with advanced disease. The presence of comorbidities precludes most from potentially curative allogeneic stem cell transplant. Due to the dearth of effective treatment options, therapeutic goals are focused on slowing progression and maintaining quality of life. Median overall survival varies across MPN subtypes, ranging from 15.4 years for patients with low-risk disease to 1.3 years for those with high-risk disease. Furthermore, MPNs are also associated with a risk for transformation to acute myeloid leukemia, where the 5-year overall survival rate is only 25%.

TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the management of patients with myelofibrosis.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Identify the clinical signs and symptoms of myelofibrosis
• Differentiate emerging efficacy and safety data on JAK inhibitor therapy for myelofibrosis
• Apply strategies to manage symptoms and optimize quality of life in patients receiving treatment for myelofibrosis

FACULTY

Alice Lynn, ANP (Chairperson)
Advanced Nurse Practitioner
MD Anderson Cancer Center

Dawn C. Urbanovsky, RN, BSN, OCN^®
Oncology Nurse
MD Anderson Cancer Center

REGISTRATION

There is no fee to participate in or claim NCPD credit for this activity.

Provided by

Nursing Continuing Professional Development

i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this NCPD activity. This activity has been designated for 0.3 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN^®, CPHON^®, CBCN^®, AOCNP^®, AOCNS^®, and BMTCN^®renewal candidates may apply 1 ILNA point toward:

• Basic Concepts for Transplantation
• Care Continuum
• Diagnosis and Staging
• Foundation of Transplant
• Oncology Nursing Practice
• Scientific Basis for Practice
• Survivorship
• Symptom Management
• Treatment
• Type of Transplants and Sources of Stem Cells

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS

i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of a NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

Alice Lynn, ANP, has no relevant financial relationships to disclose.

Dawn C. Urbanovsky, RN, BSN, OCN^®, has no relevant financial relationships to disclose.

The i3 Health planners and managers have nothing to disclose.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must:

1. Take the pretest
2. Watch the video
3. Pass the posttest with a score of ≥80%
4. Complete the activity evaluation
5. Download or print their Certificate of Credit

UNAPPROVED USE DISCLOSURE

i3 Health requires NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Incyte.

Aggregate participant data will be shared with commercial supporters of this activity.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it.

Start Activity